(Q73432129)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

title

Docetaxel in combination with epirubicin in metastatic breast cancer: pharmacokinetic interactions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

main subject

metastatic breast cancer

1 reference

1 reference

1 reference

M Ceruti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

V Tagini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

V Recalenda

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

S Arpicco

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

L Cattel

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

M Airoldi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

C Bumma

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

publication date

1 November 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

issue

11-12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

page(s)

733-739

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer

3 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Mechanism of action of taxol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Relationships between the structure of taxol analogs and their antimitotic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Effects of Taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Current status of Taxotere (docetaxel) as a new treatment in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Docetaxel in stage III and IV non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Phase I trial of Taxotere: five-day schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Evaluation of the linearity of docetaxel pharmacokinetics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Biochemistry of multidrug resistance mediated by the multidrug transporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Measurement of cremophor EL following taxol: plasma levels sufficient to reverse drug exclusion mediated by the multidrug-resistant phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

Reversal of multidrug resistance by surfactants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-827X%2899%2900092-0

10.1016/S0014-827X(99)00092-0

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10668172%20AND%20SRC:MED&resulttype=core&format=json

3 November 2019

1 reference